← Leaderboards
William C Hahn
Dana-Farber Cancer Institute
$46,384,528
Attributed
$54,275,079
Total exposure
24
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$54,275,079 · 24
By mechanism
U01$21,635,233 · 5
R01$11,871,365 · 5
P01$10,243,736 · 7
RC2$6,635,349 · 1
R33$1,587,310 · 1
P50$1,272,793 · 2
Top collaborators
- Andrew James Aguirre4 shared
- Stephanie Dougan4 shared
- Todd R. Golub4 shared
- Lynda Chin3 shared
- Nancy E. Kohl1 shared
- Robert Thomas Manguso1 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Charles Stiles$20,855,954
- Thomas M Roberts$29,815,975
- Karl Hsu$475,430
- Todd R. Golub$52,404,583
- Andrew L Kung$5,571,759
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMutationCellsTumorOncogenesBasePathway InteractionsInsightGeneticFoundationsSignal PathwaySignal TransductionPhosphotransferasesProteinsOncogenicMolecularComplexProgramsTherapeutic TargetGenesTranslational StudyMutateBiologicalInhibitor/Antagonist
Grant awards (108)
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity$1,037,023
U01 · FY2025 · CA · contact PI
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers$657,156
R01 · FY2025 · CA · contact PI
Investigating CREB5-driven mechanisms of immune therapy resistance$620,820
R01 · FY2025 · CA
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity$985,172
U01 · FY2024 · CA · contact PI
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers$624,299
R01 · FY2024 · CA · contact PI
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity$1,037,023
U01 · FY2023 · CA · contact PI
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers$651,215
R01 · FY2023 · CA · contact PI
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity$1,037,023
U01 · FY2022 · CA · contact PI
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models$963,693
U01 · FY2022 · CA · contact PI
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers$682,670
R01 · FY2022 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$1,007,904
U01 · FY2021 · CA · contact PI
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models$963,150
U01 · FY2021 · CA · contact PI
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens$568,413
U01 · FY2021 · CA · contact PI
PROJECT 4: Interrogating PP2A Signaling in Human Cancers$326,362
P01 · FY2021 · CA · contact PI
Project 2: Identification of combination therapy for KRAS-driven lung cancers.$288,552
P01 · FY2021 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$1,007,637
U01 · FY2020 · CA · contact PI
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models$1,004,910
U01 · FY2020 · CA · contact PI
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens$611,615
U01 · FY2020 · CA · contact PI
PROJECT 4: Interrogating PP2A Signaling in Human Cancers$326,362
P01 · FY2020 · CA · contact PI
Project 2: Identification of combination therapy for KRAS-driven lung cancers.$288,552
P01 · FY2020 · CA · contact PI
Novel genetic dependencies in VRK2 methylated glioblastoma multiforme$178,000
R03 · FY2020 · TR · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$968,937
U01 · FY2019 · CA · contact PI
Systematic identification of oncogenic KRAS synthetic lethal interactions$499,996
U01 · FY2019 · CA · contact PI
PROJECT 4: Interrogating PP2A Signaling in Human Cancers$316,571
P01 · FY2019 · CA · contact PI
Project 2: Identification of combination therapy for KRAS-driven lung cancers.$288,552
P01 · FY2019 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$1,007,876
U01 · FY2018 · CA · contact PI
Systematic identification of oncogenic KRAS synthetic lethal interactions$807,776
U01 · FY2018 · CA · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$371,117
R01 · FY2018 · CA · contact PI
PROJECT 4: Interrogating PP2A Signaling in Human Cancers$326,362
P01 · FY2018 · CA · contact PI
Project 2: Identification of combination therapy for KRAS-driven lung cancers.$288,552
P01 · FY2018 · CA · contact PI
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens$1,845,039
U01 · FY2017 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$1,027,367
U01 · FY2017 · CA · contact PI
Systematic identification of oncogenic KRAS synthetic lethal interactions$807,776
U01 · FY2017 · CA · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$371,117
R01 · FY2017 · CA · contact PI
PROJECT 4: Interrogating PP2A Signaling in Human Cancers$328,830
P01 · FY2017 · CA · contact PI
Project 2: Identification of combination therapy for KRAS-driven lung cancers.$288,552
P01 · FY2017 · CA · contact PI
Defining Novel Therapeutic Strategies for KRAS-Mutant CRC$283,132
P50 · FY2017 · CA · contact PI
Systematic identification of oncogenic KRAS synthetic lethal interactions$807,776
U01 · FY2016 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$698,459
U01 · FY2016 · CA · contact PI
Identification of TBK1 inhibitors in KRAS-dependent lung cancer$398,433
P01 · FY2016 · CA · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$371,117
R01 · FY2016 · CA · contact PI
Defining Novel Therapeutic Strategies for KRAS-Mutant CRC$265,088
P50 · FY2016 · CA · contact PI
Systematic identification of oncogenic KRAS synthetic lethal interactions$817,805
U01 · FY2015 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$703,315
U01 · FY2015 · CA · contact PI
Identification of TBK1 inhibitors in KRAS-dependent lung cancer$398,433
P01 · FY2015 · CA · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$371,117
R01 · FY2015 · CA · contact PI
Druggable Genetic Lesions in Pediatric Astrocytoma$344,049
P01 · FY2015 · CA · contact PI
Defining Novel Therapeutic Strategies for KRAS-Mutant CRC$212,517
P50 · FY2015 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$693,679
U01 · FY2014 · CA · contact PI
Identification of TBK1 inhibitors in KRAS-dependent lung cancer$386,481
P01 · FY2014 · CA · contact PI
Investigations on the role of the CDK8 oncogene in colon cancer$379,240
R01 · FY2014 · CA · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$371,117
R01 · FY2014 · CA · contact PI
Regulation and Function of hTERT in Human Cells$344,831
R01 · FY2014 · AG · contact PI
Druggable Genetic Lesions in Pediatric Astrocytoma$333,065
P01 · FY2014 · CA · contact PI
Defining Novel Therapeutic Strategies for KRAS-Mutant CRC$265,679
P50 · FY2014 · CA · contact PI
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center$725,869
U01 · FY2013 · CA · contact PI
Investigations on the role of the CDK8 oncogene in colon cancer$367,642
R01 · FY2013 · CA · contact PI
Regulation and Function of hTERT in Human Cells$325,864
R01 · FY2013 · AG · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$313,646
R01 · FY2013 · CA · contact PI
Druggable Genetic Lesions in Pediatric Astrocytoma$311,514
P01 · FY2013 · CA · contact PI
Interactions of the SV40 Small t Antigen and PP2A in Human Cell Transformation$302,520
P01 · FY2013 · CA · contact PI
Defining Novel Therapeutic Strategies for KRAS-Mutant CRC$246,377
P50 · FY2013 · CA · contact PI
Identification of TBK1 inhibitors in KRAS-dependent lung cancer$236,605
P01 · FY2013 · CA · contact PI
Gene Function Manipulation Core$192,603
P01 · FY2013 · CA · contact PI
Discovering modulators of PAX8 for targeting ovarian cancer$42,438
R03 · FY2013 · MH · contact PI
Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian Cancer$639,047
RC2 · FY2012 · CA · contact PI
Identification of TBK1 inhibitors in KRAS-dependent lung cancer$429,576
P01 · FY2012 · CA · contact PI
Investigations on the role of the CDK8 oncogene in colon cancer$391,243
R01 · FY2012 · CA · contact PI
Druggable Genetic Lesions in Pediatric Astrocytoma$376,751
P01 · FY2012 · CA · contact PI
Regulation and Function of hTERT in Human Cells$344,831
R01 · FY2012 · AG · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$334,550
R01 · FY2012 · CA · contact PI
Interactions of the SV40 Small t Antigen and PP2A in Human Cell Transformation$324,857
P01 · FY2012 · CA · contact PI
Gene Function Manipulation Core$205,413
P01 · FY2012 · CA · contact PI
Discovering modulators of PAX8 for targeting ovarian cancer$43,750
R03 · FY2012 · MH · contact PI
Investigations on the role of the CDK8 oncogene in colon cancer$391,374
R01 · FY2011 · CA · contact PI
Druggable Genetic Lesions in Pediatric Astrocytoma$381,477
P01 · FY2011 · CA · contact PI
Regulation and Function of hTERT in Human Cells$344,831
R01 · FY2011 · AG · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$335,392
R01 · FY2011 · CA · contact PI
Interactions of the SV40 Small t Antigen and PP2A in Human Cell Transformation$327,979
P01 · FY2011 · CA · contact PI
Gene Function Manipulation Core$205,942
P01 · FY2011 · CA · contact PI
Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian Cancer$2,998,170
RC2 · FY2010 · CA · contact PI
Integrated genomic approaches to identify and validate cancer targets$538,078
R33 · FY2010 · CA · contact PI
Regulation and Function of hTERT in Human Cells$356,700
R01 · FY2010 · AG · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$344,428
R01 · FY2010 · CA · contact PI
Interactions of the SV40 Small t Antigen and PP2A in Human Cell Transformation$338,428
P01 · FY2010 · CA · contact PI
Gene Function Manipulation Core$211,975
P01 · FY2010 · CA · contact PI
Investigations on the role of the CDK8 oncogene in colon cancer$178,372
R01 · FY2010 · CA · contact PI
Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian Cancer$2,998,132
RC2 · FY2009 · CA · contact PI
Integrated genomic approaches to identify and validate cancer targets$531,473
R33 · FY2009 · CA · contact PI
Regulation and function of IKKe in breast cancer initiation and maintenance$345,891
R01 · FY2009 · CA · contact PI
Interactions of the SV40 Small t Antigen and PP2A in Human Cell Transformation$330,557
P01 · FY2009 · CA · contact PI
Gene Function Manipulation Core$206,658
P01 · FY2009 · CA · contact PI
Integrated genomic approaches to identify and validate cancer targets$517,759
R33 · FY2008 · CA · contact PI
Regulation and Function of Telomerase in Human Cells$321,766
R01 · FY2008 · AG · contact PI
Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation$251,034
P01 · FY2008 · CA · contact PI
Regulation and Function of Telomerase in Human Cells$328,332
R01 · FY2007 · AG · contact PI
Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation$248,508
P01 · FY2007 · CA · contact PI
Regulation and Function of Telomerase in Human Cells$338,137
R01 · FY2006 · AG · contact PI
Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation$173,009
P01 · FY2006 · CA · contact PI
Regulation and Function of Telomerase in Human Cells$346,275
R01 · FY2005 · AG
New Models of Human Cancer$157,437
K01 · FY2005 · CA
Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation$132,447
P01 · FY2005 · CA
Regulation and Function of Telomerase in Human Cells$346,275
R01 · FY2004 · AG
New Models of Human Cancer$157,437
K01 · FY2004 · CA
Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation$128,175
P01 · FY2004 · CA
New Models of Human Cancer$157,437
K01 · FY2003 · CA
New Models of Human Cancer$157,437
K01 · FY2002 · CA
New Models of Human Cancer$135,357
K01 · FY2001 · CA